Anzeige

Strophanthin

Zeitschrift: Die Medizinische Welt – aus der Wissenschaft in die Praxis
ISSN: 0025-8512
Ausgabe: 2015 (Vol. 66): Heft 6 2015
Seiten: 275-280

  1. Ghysel-Burton J, Godfraind T. Stimulation and inhibition of the sodium pump by cardioactive steroids in relation to their binding sites and their inotropic effect on guinea-pig isolated atria. Br J Pharmacol 1979; 66: 175-184. DOI:10.1111/j.1476-5381.1979.tb13662.x
  2. De Pover A, Godfraind T. Interaction of ouabain with (Na++K+)ATPase from human heart and from guinea-pig heart. Biochem Pharmacol 1979; 28: 3051-3058. DOI:10.1016/0006-2952(79)90612-9
  3. Godfraind T. Stimulation and inhibition of the Na+/K+-pump by cardiac glycosides. In: Greeff K (ed.): Cardiac Glycosides, Handbook of Experimental Pharmacology, Band 56/I. Berlin, Heidelberg, New York: Springer 1981; 381-393
  4. Oselkin M et al. Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. Neurosci Lett 2010; 67: 67-71. DOI:10.1016/j.neulet.2009.10.021
  5. Von Lewinski D et al. Mechanistic insight into the functional and toxic effects of strophanthidin in the failing human myocardium. Eur J Heart Fail 2007; 9: 1086-1094. DOI:10.1016/j.ejheart.2007.08.004
  6. Greeff K et al. Zur Pharmakokinetik des g-Strophanthin. Verh Dtsch Ges Kreislaufforsch 1974; 40: 301-305.
  7. Selden R et al. Ouabain pharmacokinetics in dog and man. Circulation 1972; 45: 1176-1182. DOI:10.1161/01.CIR.45.6.1176
  8. Edens E. Die Digitalisbehandlung. 3. Auflage. Berlin, München: Urban&Schwarzenberg, 1948
  9. Nesher M et al. Ouabain attenuates other cardiac steroid-induced cardiotoxicity. Br J Pharmacol 2010; 160: 346-354. DOI:10.1111/j.1476-5381.2010.00701.x
  10. Hamlyn JM et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991; 88: 6259-6263. DOI:10.1073/pnas.88.14.6259
  11. Manunta P et al. Endogenous ouabain in cardiovascular function and disease. J Hypertens 2009; 27: 9-18. DOI:10.1097/HJH.0b013e32831cf2c6
  12. Baecher S et al. No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS. Clin Chim Acta 2014; 431: 87-92. DOI:10.1016/j.cca.2014.01.038
  13. Lewis LK et al. Endogenous ouabain is not ouabain. Hypertension 2014; 64: 680-683. DOI:10.1161/HYPERTENSIONAHA.114.03919
  14. Staessen JA et al. Main results of the ouabain and adducin for specific intervention on sodium in hypertension trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials 2011; 12: 13. DOI:10.1186/1745-6215-12-13
  15. Ghadhanfar E et al. Wistar rats resistant to the hypertensive effects of ouabain exhibit enhanced cardiac vagal activity and elevated plasma levels of calcitonin gene-related peptide. PLOS ONE 2014; 9: e108909. DOI:10.1371/journal.pone.0108909
  16. Quest JA, Gillis RA. Carotid sinus reflex changes produced by digitalis. J Pharmacol Exp Ther 1971; 177: 650-653.
  17. Pace DG. The neuroexcitatory effects of digitalis in the cat: Ph. D. Thesis, Georgetown University School of Medicine and Dentistry, 1975
  18. Gillis RA. Cardiac sympathetic nerve activity: changes induced by ouabain and propranolol. Science 1969; 166: 508-512. DOI:10.1126/science.166.3904.508
  19. Gillis RA et al. Digitalis: a neuroexcitatory drug. Circulation 1975; 52: 739-742. DOI:10.1161/01.CIR.52.5.739
  20. Satoh E, Nakazato Y. On the mechanism of ouabain-induced release of acetylcholine from synaptosomes. J Neurochem 1992; 58: 1038-1044. DOI:10.1111/j.1471-4159.1992.tb09359.x
  21. Kawada T et al. In vivo assessment of acetylcholine-releasing function at cardiac vagal nerve terminals. Am J Physiol Heart Circ Physiol 2001; 281: H139-145.
  22. Yamazaki T et al. Characterization of ouabain-induced noradrenaline and acetylcholine release from in situ cardiac autonomic nerve endings. Acta Physiol (Oxf) 2007; 191: 275-284. DOI:10.1111/j.1748-1716.2007.01749.x
  23. Gillis RA, Quest JA. The role of the nervous system in the cardiovascular effects of digitalis. Pharmacol Rev 1979; 31: 19-97.
  24. Gremels H. Über den Einfluß von Digitaliskörpern auf die energetischen Vorgänge im Säugetierherzen. Arch Exp Path Pharm 1937; 186: 625-660. DOI:10.1007/BF01865162
  25. Sharma VK et al. Ouabain stimulation of noradrenaline transport in guinea pig heart. Nature 1980; 286: 817-819. DOI:10.1038/286817a0
  26. Gutman Y, Boonyaviroj P. Mechanism of inhibition of catecholamine release from adrenal medulla by diphenylhydantoin and by low concentrations of ouabain (10(-10)M). Naunyn Schmiedebergs Arch Pharmacol 1977; 296: 293-296. DOI:10.1007/BF00498696
  27. Blomquist TM et al. Source of intrinsic innervation of canine ventricle: a functional study. Am J Physiol 1987; 252: H638-H644.
  28. Zipes DP. Influence of myocardial ischemia on autonomic innervation of heart. Circulation 1990; 82: 1095-1105. DOI:10.1161/01.CIR.82.4.1095
  29. Löffelholz K, Pappano AJ. The parasympathetic neuroeffector junction of the heart. Pharmacol Rev 1985; 37: 1-24.
  30. Gremels H. Die vegetativ-hormonale Stoffwechselsteuerung und ihre Bedeutung für die Pharmakologie. Klin Wochenschr 1947; 24/25: 449-453
  31. Lei B et al. Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. Proc Natl Acad Sci USA 2005; 102: 6966-6971. DOI:10.1073/pnas.0500768102
  32. Levine SA. Carotid sinus massage. A new diagnostic test for angina pectoris. JAMA 1962; 182: 1332-1334.
  33. Lown B. Die verlorene Kunst des Heilens. Stuttgart: Schattauer 2007
  34. Braunwald E et al. Relief of angina pectoris by electrical stimulation of the carotid sinus nerves. N Engl J Med 1967; 277: 1278-1283. DOI:10.1056/NEJM196712142772402
  35. Dohrmann RE et al. Klinisch-poliklinische Studie über die Wirksamkeit von g-Strophanthin bei Angina pectoris und Myokardinfarkt. Cardiol Bull 1977; 14/15: 183-187
  36. Dohrmann RE, Dohrmann M. Neue Therapie der instabilen Angina pectoris bei koronarer Herzerkrankung. Erfahrungsheilkunde 1984; 33: 183-190.
  37. Salz H, Schneider B. Perlinguales Strophanthin bei stabiler Angina pectoris. Z Allg Med 1985; 61: 1223-1228.
  38. Lown B et al. Effect of a digitalis drug on ventricular premature beats. N Engl J Med 1977; 296: 301-306. DOI:10.1056/NEJM197702102960603
  39. Podrid P et al. Effects of acetyl-strophanthidin on left ventricular function and ventricular arrhythmias. Am Heart J 1984; 107: 882-887. DOI:10.1016/0002-8703(84)90822-6
  40. Scheiner-Bobis G et al. Signaling pathways involving sodium pump stimulate endothelin-1-secretion and nitric oxide production in endothelial cells. Cell Moll Biol (Noisy-le-grand) 2006; 30: 58-63.
  41. Hernanz R et al. Ouabain treatment increases nitric oxide bioavailability and decreases superoxide anion production in cerebral vessels. J Hypertens 2008; 26: 1944-1954. DOI:10.1097/HJH.0b013e328308de55
  42. Chorvatova A et al. Effect of ouabain on metabolic state in living cardiomyocytes evaluated by time-resolved spectroscopy of endogenous NAD(P)H fluorescence. J Biomed Opt 2012; 17: 101505. DOI:10.1117/1.JBO.17.10.101505
  43. Liu LP et al. Ouabain stimulates atrial natriuretic peptide secretion via the endothelin-1/ET(B) receptor-mediated pathway in beating rabbit atria. Life Sci 2012; 90: 793-798. DOI:10.1016/j.lfs.2012.04.008
  44. Schlossmann J, Schimer E. cGMP becomes a drug target. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 243-252. DOI:10.1007/s00210-012-0730-6
  45. Aperia A. New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target. J Intern Med 2007; 261: 44-52. DOI:10.1111/j.1365-2796.2006.01745.x
  46. Garlid KD et al. Cardioprotective signaling to mitochondria. J Moll Cell Cardiol 2009; 46: 858-866. DOI:10.1016/j.yjmcc.2008.11.019
  47. Pasdois P et al. Ouabain protects rat hearts against ischemia-reperfusion injury via pathway involving src kinase, mitoKATP, and ROS. Am J Physiol Heart Circ Physiol 2007; 292: H1470-1478. DOI:10.1152/ajpheart.00877.2006
  48. Pierre SV et al. Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts. Cardiovasc Res 2007; 73: 488-496. DOI:10.1016/j.cardiores.2006.11.003
  49. Löhr E et al. Beitrag zur Membranpermeabilität von Cardiaca (g-Strophanthin, Digoxin und Oxyfedrin) auf Grund von Mikro-Autoradiographien am Meerschweinchenherzen. Arzneimittelforschung 1971; 21: 921-927.
  50. Nunez-Duran H, Fernandez P. Evidence for an intracellular site of action in the heart for two hydrophobic cardiac steroids. Life Sci 2004; 74: 1337-44. DOI:10.1016/j.lfs.2003.07.041
  51. Tian J, Xie XJ. The Na-K-ATPase and calcium-signaling microdomains. Physiology (Bethesda) 2008; 23: 205-211. DOI:10.1152/physiol.00008.2008
  52. Sagawa T et al. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol 2002; 282: H1118-H1126. DOI:10.1152/ajpheart.00700.2001
  53. Erdle HP et al. Resorption und Ausscheidung von g-Strophanthin nach intravenöser und perlingualer Gabe. Dtsch Med Wochenschr 1979; 104: 976-979. DOI:10.1055/s-0028-1129021
  54. Adams KF Jr et al. A perspective on re-evaluating digoxin’s role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. Eur J Heart Fail 2014; 16: 483-493. DOI:10.1002/ejhf.64
  55. Agostini PG et al. Long-term use of k-strophanthin in advanced congestive heart failure due to dilated cardiomyopathy: a double-blind crossover evaluation versus digoxin. Clin Cardiol 1994; 17: 536-554. DOI:10.1002/clc.4960171005
  56. Ban K et al. . On the mechanism of the failure of mitochondrial function in isolated guinea-pig myocytes subjected to a Ca2+ overload. Cardiovasc Res 1999; 44: 556-567. DOI:10.1016/S0008-6363(99)00233-3
  57. Obata T et al. Evidence of hydroxyl free radical generation by calcium overload in rat myocardium. J Pharm Pharmacol 1997; 49: 787-90. DOI:10.1111/j.2042-7158.1997.tb06113.x
  58. Schatzmann HJ. Herzglykoside als Hemmstoffe für den aktiven Kalium- und Natriumtransport durch die Erythrozytenmembran. Helv Physiol Pharmacol Acta 1953; 11: 346-354.
  59. Vassalle M, Lin CI. Calcium overload and cardiac function. J Biomed Sci 2004; 11: 542-565. DOI:10.1007/BF02256119
  60. Li T, Vassalle M. The negative inotropic effect of calcium overload in cardiac purkinje fibers. J Moll Cell Cardiol 1984; 16: 65-77. DOI:10.1016/S0022-2828(84)80715-4
  61. Aceto E, Vassalle M. On the mechanism of the positive inotropy of low concentrations of strophanthidin. J Pharmacol Exp Ther 1991; 259: 182-189.
  62. Brembach H. Infarktvorbeugung in der Arbeitsmedizin. Notabene medici 1984; 7: 613-616.
  63. Von Ardenne M. Research on the mechanism of myocardial infarction and on counteracting measures, a new galenic form of the fast acting g-strophanthin. Agressologie 1978; 19: 13-22.
  64. Morgan EE et al. Preconditioning by subinotropic doses of ouabain in the Langendorff perfused rabbit heart. J Cardiovasc Pharmacol 2010; 55: 234-239. DOI:10.1097/FJC.0b013e3181ce5e14
  65. Dreifuss JJ et al. Electrophysiology of oxytocin actions on central neurons. Ann NY Acad Sci 1992; 652: 46-57. DOI:10.1111/j.1749-6632.1992.tb34345.x
  66. Houshmand F et al. Role of Natriuretic Peptide in Oxitocin induced Cardioprotection. Heart Lung Circ 2015; 24: 86-93. DOI:10.1016/j.hlc.2014.05.023
  67. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001: 81: 629-683
  68. Campia I et al. Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. Biochem J 2012; 447: 301-311. DOI:10.1042/BJ20120200
  69. www.herzinfarkt-alternativen.de

Artikel, die Sie auch interessant finden könnten...

1.

T. Müller-Tasch 1, N. Holzapfel 1, J. Jünger 1, C. Zugck 2, A. Remppis 2, H. A. Katus 2, W. Herzog1

Die Medizinische Welt 2007 58 1: 13-16

2.

H.-D. Düngen, J. Heidelk, M. Krüger, F. Krackhardt, W. Haverkamp, für das Teilprojekt 12 des Kompetenznetzes Herzinsuffizienz, BMBF

Die Medizinische Welt 2007 58 1: 5-10

3.
D. Tschöpe

Die Medizinische Welt 2006 57 5: 201-204



aus der MedWelt-Redaktion

Die Medizinische Welt 05/2017: YouTube als Plattform für Ärzte

Videos, die von Ärzten produziert werden, stellen einen nicht zu unterschätzenden Mehrwert für...

"Die Medizinische Welt" kooperiert mit der Deutschen Hochdruckliga

Anlässlich des 40. Wissenschaftlichen Kongresses der Deutschen Hochdruckliga e.V. (DHL) publiziert...

Neues Mitglied im wissenschaftlichen Beirat der MedWelt

Der Beirat der Schattauer-Fachzeitschrift „Medizinische Welt“ gewinnt mit Professor Dr. med....